PT  - JOURNAL ARTICLE
AU  - Hong Su
AU  - David W. Boulton
AU  - Anthony Barros, Jr.
AU  - Lifei Wang
AU  - Kai Cao
AU  - Samuel J. Bonacorsi, Jr.
AU  - Ramaswamy A. Iyer
AU  - W. Griffith Humphreys
AU  - Lisa J. Christopher
TI  - Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human
AID  - 10.1124/dmd.112.045450
DP  - 2012 Jul 01
TA  - Drug Metabolism and Disposition
PG  - 1345--1356
VI  - 40
IP  - 7
4099  - http://dmd.aspetjournals.org/content/40/7/1345.short
4100  - http://dmd.aspetjournals.org/content/40/7/1345.full
SO  - Drug Metab Dispos2012 Jul 01; 40
AB  - Saxagliptin is a potent dipeptidyl peptidase-4 inhibitor approved for the treatment of type 2 diabetes mellitus. The pharmacokinetics and disposition of [14C]saxagliptin were investigated in healthy male subjects after a single 50-mg (91.5 μCi) oral dose. Saxagliptin was rapidly absorbed (Tmax, 0.5 h). Unchanged saxagliptin and 5-hydroxy saxagliptin (M2), a major, active metabolite, were the prominent drug-related components in the plasma, together accounting for most of the circulating radioactivity. Approximately 97% of the administered radioactivity was recovered in the excreta within 7 days postdose, of which 74.9% was eliminated in the urine and 22.1% was excreted in the feces. The parent compound and M2 represented 24.0 and 44.1%, respectively, of the radioactivity recovered in the urine and feces combined. Taken together, the excretion data suggest that saxagliptin was well absorbed and was subsequently cleared by both urinary excretion and metabolism; the formation of M2 was the major metabolic pathway. Additional minor metabolic pathways included hydroxylation at other positions and glucuronide or sulfate conjugation. Cytochrome P450 (P450) enzymes CYP3A4 and CYP3A5 metabolized saxagliptin and formed M2. Kinetic experiments indicated that the catalytic efficiency (Vmax/Km) for CYP3A4 was approximately 4-fold higher than that for CYP3A5. Therefore, it is unlikely that variability in expression levels of CYP3A5 due to genetic polymorphism will impact clearance of saxagliptin. Saxagliptin and M2 each showed little potential to inhibit or induce important P450 enzymes, suggesting that saxagliptin is unlikely to affect the metabolic clearance of coadministered drugs that are substrates for these enzymes.